Literature DB >> 11135626

Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway.

K Chitaley1, C J Wingard, R Clinton Webb, H Branam, V S Stopper, R W Lewis, T M Mills.   

Abstract

Relaxation of the smooth muscle cells in the cavernosal arterioles and sinuses results in increased blood flow into the penis, raising corpus cavernosum pressure to culminate in penile erection. Nitric oxide, released from non-adrenergic/non-cholinergic nerves, is considered the principle stimulator of cavernosal smooth muscle relaxation, however, the inhibition of vasoconstrictors (that is, norepinephrine and endothelin-1, refs. 5-9) cannot be ignored as a potential regulator of penile erection. The calcium-sensitizing rho-A/Rho-kinase pathway may play a synergistic role in cavernosal vasoconstriction to maintain penile flaccidity. Rho-kinase is known to inhibit myosin light chain phosphatase, and to directly phosphorylate myosin light-chain (in solution), altogether resulting in a net increase in activated myosin and the promotion of cellular contraction. Although Rho-kinase protein and mRNA have been detected in cavernosal tissue, the role of Rho-kinase in the regulation of cavernosal tone is unknown. Using pharmacologic antagonism (Y-27632, ref. 13, 18), we examined the role of Rho-kinase in cavernosal tone, based on the hypothesis that antagonism of Rho-kinase results in increased corpus cavernosum pressure, initiating the erectile response independently of nitric oxide. Our finding, that Rho-kinase antagonism stimulates rat penile erection independently of nitric oxide, introduces a potential alternate avenue for the treatment of erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135626     DOI: 10.1038/83258

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  79 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell mice.

Authors:  Trinity J Bivalacqua; Ashley E Ross; Travis D Strong; Milena A Gebska; Biljana Musicki; Hunter C Champion; Arthur L Burnett
Journal:  Urology       Date:  2010-06-09       Impact factor: 2.649

3.  The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum.

Authors:  Selim Cellek
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 4.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

5.  Nitrergic Mechanisms for Management of Recurrent Priapism.

Authors:  Uzoma A Anele; Arthur L Burnett
Journal:  Sex Med Rev       Date:  2015-06-04

6.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

7.  Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis.

Authors:  Trinity J Bivalacqua; Tongyun Liu; Biljana Musicki; Hunter C Champion; Arthur L Burnett
Journal:  Eur Urol       Date:  2006-11-10       Impact factor: 20.096

8.  Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle.

Authors:  Alexandra Wibberley; Zunxuan Chen; Erding Hu; J Paul Hieble; Timothy D Westfall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

9.  Molecular targets for diabetes mellitus-associated erectile dysfunction.

Authors:  Elizabeth Yohannes; Jinsook Chang; Moses T Tar; Kelvin P Davies; Mark R Chance
Journal:  Mol Cell Proteomics       Date:  2009-12-10       Impact factor: 5.911

Review 10.  The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction.

Authors:  Karl Swärd; Mitsuo Mita; David P Wilson; Jing Ti Deng; Marija Susnjar; Michael P Walsh
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.